NEW YORK, February 25 (newratings.com) - Analysts at Roth Capital initiate coverage of Keryx Biopharma (KERX) with a "buy" rating. The target price is set to $7.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.